Evomela
Adult Central Nervous System Germ Cell Tumor
City of Hope Medical CenterPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Adult Central Nervous System Germ Cell Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Palbociclib Abramson Cancer Center at Penn Medicine | Phase 2 | B |
Palifosfamide-Tris Indiana University | Phase 2 | CCC |
Busulphan City of Hope Medical Center | Phase 1 | CC |
FILGRASTIM City of Hope Medical Center | Phase 1 | CC |
Hycamtin City of Hope Medical Center | Phase 1 | CC |
EF-5 National Cancer Institute (NCI) | Phase 1 | C |
Same molecule, other indications
Evomela is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →